{
    "clinical_study": {
        "@rank": "157953", 
        "arm_group": {
            "arm_group_label": "MEDI-546", 
            "arm_group_type": "Experimental", 
            "description": "MEDI-546, IV q4wks for 104 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the long-term safety of MEDI-546 in adults with\n      moderate to severe active systemic lupus erythematosus"
        }, 
        "brief_title": "An Open-label Study to Evaluate the Long-term Safety of MEDI-546, a Product Under Investigation for the Treatment of Systemic Lupus Erythematosus, in Adults", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Lupus Erythematosus, Systemic", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label extension study to evaluate long-term safety and tolerability of\n      intravenous (IV) MEDI-546 in adult subjects with moderately-to-severely active systemic\n      lupus erythematosus (SLE). Subjects must have completed the qualifying Phase 2 study and\n      meet this study criteria in order to be eligible."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be willing to use 2 methods of effective contraception\n\n          -  Must have venous access\n\n          -  Must be willing to forego participation in other clinical trials for SLE.\n\n        Exclusion Criteria:\n\n          -  Any concurrent condition that in the opinion of the investigator would interfere with\n             the evaluation of the investigational product\n\n          -  Major surgery within 8 weeks before signing ICF\n\n          -  Elective major surgery planned during the study period\n\n          -  Concomitant Medications within the last 12 weeks:  Azathioprine > 200 mg/day,\n             Mycophenolate mofetil/mycophenolic acid > 2.0 g/day, Oral, SC, or intramuscular\n             methotrexate > 25 mg/week\n\n          -  A live or attenuated vaccine within 4 weeks of signing the ICF\n\n          -  Bacillus of Calmette and Gu\u00e9rin (BCG) vaccine within 1 year of ICF"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "68 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753193", 
            "org_study_id": "CD-IA-MEDI-546-1145", 
            "secondary_id": "2012-004619-30"
        }, 
        "intervention": {
            "arm_group_label": "MEDI-546", 
            "description": "MEDI-546, IV q4wks for 104 weeks", 
            "intervention_name": "MEDI-546", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Systemic Lupus Erythematosus", 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Desert", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Upland", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockbridge", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tulsa", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barranquilla", 
                        "country": "Colombia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bucaramanga", 
                        "country": "Colombia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chia", 
                        "country": "Colombia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Medellin", 
                        "country": "Colombia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seodaemun-gu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guadalajara", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leon", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toluca", 
                        "country": "Mexico"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arequipa", 
                        "country": "Peru"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Colombia", 
                "Korea, Republic of", 
                "Mexico", 
                "Peru"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Brazil: Ministry of Health", 
                "Colombia: National Institutes of Health", 
                "Czech Republic: State Institute for Drug Control", 
                "Mexico: Ministry of Health", 
                "Peru: Ministry of Health", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Taiwan: Department of Health", 
                "Ukraine: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "safety and tolerability will be assessed primarily by summarizing treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753193"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Immunogenicity will be measured by laboratory assessments looking for anti-drug antibodies", 
            "measure": "Immunogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}